Evidence map›Paper›PMID 27980608›Full record

ArticleInfectious agents and cancer2016

Human papillomavirus genotypes and HPV-16 variants distribution among Tunisian women with normal cytology and squamous intraepithelial lesions.

R Ghedira, W Mahfoudh, S Hadhri, S Gabbouj, I Bouanene, H Khairi, A Chaieb, R Khelifa, N Bouaouina, S Remadi and 7 more

Open access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

R GhediraMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia ; Faculty of Sciences, Carthage University, Bizerte, Tunisia.
W MahfoudhMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
S HadhriNational Office of Family and Population, Monastir, Tunisia.
S GabboujMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
I BouaneneDepartment of Epidemiology and preventive medicine, Faculty of Medicine, Monastir University, Monastir, Tunisia.
H KhairiMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia ; Department of Gynecology Obstetrics, Farhat Hached University Hospital, Sousse, Tunisia.
A ChaiebMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia ; Department of Gynecology Obstetrics, Farhat Hached University Hospital, Sousse, Tunisia.
R KhelifaUnit of Viral and Molecular Tumor Diagnostics, Habib Thameur Hospital, Tunis, Tunisia.
N BouaouinaMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia ; Department of Cancerology Radiotherapy, Farhat Hached University Hospital, Sousse, Tunisia.
S RemadiLaboratory of Anatomy and Pathologic cytology, Sousse, Tunisia.
A A ElmiDepartment of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
D BansalDepartment of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
A A SultanDepartment of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
R FalehDepartment of Gynecology and Obstetrics, University Hospital of Monastir, Monastir, Tunisia.
A ZakhamaMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
L ChouchaneLaboratory of Genetic Medicine and Immunology, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
E HassenMolecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia ; Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.
University of Monastir · TNWeill Cornell Medical College in Qatar · QAHabib hospital Thameur · TNHôpital Farhat Hached · TNUniversity of Sousse · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about the epidemiological characteristics of papillomavirus (HPV) infection among North African countries. Herein, we conducted a molecular epidemiological study to investigate prevalence of HPV type and HPV-16 variants among cervical-screened unvaccinated Tunisian women.

methodsCross-sectional study was performed on 494 Tunisian women visiting Women's Healthcare Centers. HPV-DNA detection was carried out on cervical samples using real-time polymerase chain reaction. HPV genotyping and HPV-16 variants were characterized by direct sequencing of

resultsThe overall HPV prevalence was 34% (95% CI: 30-38%) with significantly higher prevalence among women with squamous intraepithelial lesions (SIL) than those with no intraepithelial lesions (NIL) 84% (95% CI: 76-92%) and 24.5% (95% CI: 20-29%) respectively. The distribution of HPV prevalence according to women's age shows a U-shaped curve and the highest HPV prevalence rates were observed among the youngest (≤25 years; 51.2%, 95% CI: 37-67%) and the oldest women (>55 years; 41.7%, 95% The HPV-16 prevalence was 32.8% (95% CI: 22-45%) among women with SIL and 9.2% (95% CI: 6-12%) among women with NIL. Whereas, the HPV-18 prevalence was 1.3% (95% CI: 0-5%) among women with SIL and 0.3% (95% CI: 0-1%) among women with NIL. Among HPV-16 positive women, European lineage (E) was identified as the predominant HPV-16 variant (85.7%, 95% CI: 76-95%). The frequency of E variant was lower among SIL than among NIL women (81%, 95% CI: 64-99%, and 88%, 95% CI: 77-100%, respectively). Conversely, the African-2 variant frequency was higher among SIL than among NIL women (18%, 95% CI: 1-36% and 6%, 95% CI: 2-14%, respectively). In multivariate analysis, young age was the only risk factor that is independently associated with HPV infection. Moreover, HPV infection and menopause were both found to be independently associated with SIL and HSIL.

conclusionHPV DNA testing should be proposed to young and menopausal Tunisian women. Considering HPV prevalence, only 13% of the Tunisian women could be protected by the bivalent HPV vaccine. These results may be helpful for designing an adapted HPV testing and vaccination program in Tunisia.

Indexed as

CervixHPV-16 variantsHuman PapillomavirusPrevalenceTunisian women

Identifiers

PMID27980608
PMCPMC5133751
OpenAlexW2557972641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.